A 36-year-old man presents to a medical research institute in Los Angeles with neurological symptoms. Clinicians taking the patient's history learn that 4 years previously, he was diagnosed with an astrocytoma identified as isocitrate dehydrogenase (IDH)-mutant diffuse, with a lesion in the right frontoparietal lobe, which was surgically resected.
After the tumor recurred in the same location 6 months later, a second surgery was performed, followed by radiation therapy.
At the time of the patient's current presentation due to neurological symptoms, clinicians order a perfusion MRI, which reveals lesions in the right frontoparietal (2.5 cm) and left parieto-occipital lobes (1 cm).
Two months later, a perfusion identifies subtotal surgical resection of the tumors, and based on the pathology report, the patient is diagnosed with IDH-mutant glioblastoma multiforme (GBM).
For the next month, the patient receives standard treatment with adjuvant chemoradiation therapy with 59.4 Gy/33 fractions radiation and 75 mg/m2 temozolomide.
The patient is enrolled to receive an institutional review board-approved experimental combination immunotherapy. Consistent with FDA regulations for tissue/cell-based treatment practices, the team identifies an inhibitory killer immunoglobulin-like receptor [KIR]-human leukocyte antigen [HLA] KIR-HLA-mismatched haploidentical relative as a cell donor, a protocol based on a previously reported approach for intentionally mismatched natural killer (NK) cells.
This treatment is administered from November 2019 through January 2020. Before initiation of the experimental therapy, the patient receives pre-conditioning with a moderate dose of fludarabine (15 mg/m2/d) on days -7 through -4.
On day -1, a dose of 3 million/m2 IU interferon alpha is subcutaneously injected.
On day 0, 1.6 billion (18 million/kg) allogeneic, highly purified (>95%) IL-2 activated NK cells are administered via intravenous infusion, followed by five daily subcutaneous injections of interleukin (IL)-2 (6 million IU/m2).
Thirty days after receiving the NK cell infusion, the patient receives an intramuscular injection of tetanus-diphtheria (td) vaccine to prime a cellular immune response.
One day later, clinicians start the patient on a 21-day course of a dose-intensified (di)-temozolomide regimen (100 mg/m2).
On day 21 of the cycle, the patient is given a td vaccine, administered intradermally into his right groin area.
On days 22, 29, and 36, the patient receives 5 million viable allogeneic, monocyte-derived dendritic cells pulsed with cytomegalovirus (CMV)-pp65 antigen intradermally into the right groin area.
The case authors explain that throughout the treatment regimen, the patient also receives a cyclooxygenase-2 inhibitor at 200 mg/day, with the aim of limiting the inflammatory symptoms of the immunotherapy and immune tolerance buildup against cancer by controlling regulatory T cells.
He has no grade III or IV adverse events, and on the days he receives the cell therapies, he has mild, self-limited fever along with grade 1 lymphopenia at the end of the di-temozolomide regimens.
At assessments 1 month following NK cell infusion and 1 week after the first dendritic cell injection, contrast-enhanced MRI reveals no evidence of residual tumor. Perfusion MRIs from months 3, 6, 12, and 15 show continued complete response.
Post-immunotherapy follow-up axial T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) scans of the brain: (A) 3-month, (B) 6-month, (C) 12-month, (D) 15-month contrast-enhanced MRI images with evidence of no tumor recurrence, demonstrating durable complete response.
Discussion
Clinicians presenting this case of a young man with recurrent glioblastoma and residual tumor note that the novel treatment strategy of allogeneic NK cells combined with dendritic cells pulsed with cytomegalovirus-pp65 was associated with durable complete response.
The case authors note that although about 25% of GBM patients receiving temozolomide can survive 2 years, the median overall survival is only 9.5 months, and that outcomes are better among those with no residual tumor after surgery and those who receive long-term temozolomide.
A 2021 review of patients with newly diagnosed glioblastoma found that while the incidence is low compared with other cancers such as lung, breast, prostate, and colon cancers, it dwarfs these other tumor types in terms of average years of life lost -- i.e., 20.1 years for glioblastoma vs 6.1 years for prostate cancer and 11.8 years for lung cancer.
In addition, GBM typically affects patients in the prime of their lives. Thus, the disease represents a very important problem in oncology, with a grim prognosis that has changed little since the 1970s.
A recent evaluation of standard treatment strategies for GBM from two centers in the Netherlands found that after adjustments for confounders, patients with recurrent GBM selected for treatment with re-resection followed by adjuvant treatment or systemic treatment survived 7.3 and 11.0 months -- significantly longer than the 3.1 months noted in patients selected for best supportive care (P<0.001 for both). Survival with re-irradiation was 9.2 months, which was not significantly different for patients selected based on clinical parameters to receive best supportive care (P=0.068).
The case authors note that clinical studies of GBM patients receiving CMV-pp65 antigen-loaded dendritic cell vaccines have reported significant clinical benefits, although those studies involved patients who were already in remission or had minimal residual disease before any recurrence, and treatment used the patients' own dendritic cells.
The case authors referenced six studies of various immunotherapies that led to the hypothesis that informed their experimental treatment combination of allogeneic NK and dendritic cells pulsed with CMV-pp65.
GBMs have been linked with complex immunosuppressive effects within the tumor microenvironment, including secretion of IL-10 and transforming growth factor beta, recruitment of M2-macrophages and regulatory T cells and their upregulation of immune checkpoint ligands and major histocompatibility (MHC) class I receptors on their surface, the case authors note.
And while GBMs have responded to treatment involving adoptive transfer of T cells, studies in mice have shown that NK cells can effectively eliminate GBM, with the added benefit of minimal graft versus host disease in comparison to T cells.
Increased levels of MHC class I molecules on the surface of GBM cells can lead to immune evasion by inhibiting NK cytolytic function; the case authors suggest this might be able to be overcome with allogeneic NK cell transplantation from an MHC class I-mismatched donor.
The team cites studies showing that use of KIR-HLA-mismatched NK cell therapy helps improve elimination of glioma stem cells, and that this approach has also been effective in GBM patient-derived xenograft animal models, and in patients with advanced non-small cell lung cancer.
Dendritic cells provide a direct link from innate immunity to adaptive immune response by digesting and presenting an antigen to the adaptive immune system, the case authors explain, citing a clinical trial in which vaccination with dendritic cells plus concomitant standard therapy was associated with extended survival in GBM patients.
Furthermore, extended survival has been reported in patients vaccinated with autologous dendritic cells who received adjuvant temozolomide, which appears to enhance NK activation. The case authors note that since CNV is expressed in over 90% of GBMs, studies have appeared to link vaccination with CMV-primed dendritic cells with increases in both progression-free survival and overall survival in patients with non-recurrent GBM.
The authors explain that while their use of combination immunotherapy consisting of allogeneic NK and dendritic cells that were intentionally mismatched for inhibitory KIR/HLA reflects existing study protocols and previous reports, this is believed to be the first time the combination of both cell therapies was administered to a GBM patient with residual tumor.
Based on the reported ability of NK to target chemotherapy-resistant cancer cells and GBM stem-like cells, clinicians initiated the combination immunotherapy protocol with use of intentionally mismatched NK cells in order to address and potentially eliminate residual disease.
After the residual disease was addressed, the tumor surveillance elicited by a vaccine-based immunotherapy would have a better potential to control the disease and prevent relapse, the authors said.
And while they acknowledged that individual treatment components i.e., temozolomide, NK cells, or dendritic cells may have generated the complete response, with or without CMV-pp65, existing data along with the fact that this patient achieved complete remission for over a year shows the potential enhanced immunotherapeutic effects of intentionally and strategically mismatched allogeneic cell therapies compared with existing autologous therapy models in clinical development.
This suggests that new immunotherapy strategies are worthy of further study, the case authors stated.
Conclusion
They concluded that their patient with recurrent GBM achieved durable complete remission with a novel treatment strategy with allogeneic NK cells and dendritic cells pulsed with CMV-pp65 despite having residual tumor following surgical resection, and that if the approach is confirmed in additional patients, the approach could offer an effective therapeutic option for people with an otherwise dismal prognosis.
Disclosures
The case report authors noted no conflicts of interest.
The rest is here:
Novel Tx Helped Man With Recurrent Brain Tumor - MedPage Today
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
- The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising... - November 7th, 2023
Recent Comments